Cardiovascular Systems Inc 4
4 · Cardiovascular Systems Inc · Filed Oct 24, 2013
Insider Transaction Report
Form 4
Flaherty James E
Chief Administrative Officer
Transactions
- Sale
Common Stock
2013-10-22$26.42/sh−18,756$495,534→ 149,992 total - Sale
Common Stock
2013-10-23$30.00/sh−300$9,000→ 132,366 total - Exercise/Conversion
Common Stock
2013-10-22$8.83/sh+8,624$76,150→ 149,360 total - Sale
Common Stock
2013-10-22$27.25/sh−17,626$480,309→ 132,366 total - Exercise/Conversion
Common Stock
2013-10-22$7.90/sh+19,388$153,165→ 168,748 total - Exercise/Conversion
Common Stock
2013-10-23$12.15/sh+300$3,645→ 132,666 total - Exercise/Conversion
Stock Option (right to buy)
2013-10-22−19,388→ 0 totalExercise: $7.90Exp: 2017-08-06→ Common Stock (19,388 underlying) - Exercise/Conversion
Stock Option (right to buy)
2013-10-22−8,624→ 0 totalExercise: $8.83Exp: 2017-04-17→ Common Stock (8,624 underlying) - Exercise/Conversion
Stock Option (right to buy)
2013-10-23−300→ 23,820 totalExercise: $12.15Exp: 2017-12-11→ Common Stock (300 underlying)
Holdings
- 10,999
Stock Option (right to buy)
Exercise: $8.75Exp: 2019-03-02→ Common Stock (10,999 underlying)
Footnotes (4)
- [F1]The shares were sold pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.00 to $26.97 inclusive. The reporting person undertakes to provide Cardiovascular Systems, Inc., any security holder of Cardiovascular Systems, Inc. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.56 inclusive. The reporting person undertakes to provide Cardiovascular Systems, Inc., any security holder of Cardiovascular Systems, Inc. or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]Fully exercisable.